RAINMED-B (02297) released its interim results, reporting a net loss attributable to shareholders of 21.989 million yuan, a year-on-year decrease of 31.65%.

RAINMED-B (02297) announced its interim results for the six months ending June 30, 2026, during which the group achieved revenue of 14.672 million yuan, a year-on-year increase of 41.01%. The loss attributable to shareholders narrowed to 21.989 million yuan, down 31.65% year-on-year; the basic loss per share was 0.02 yuan. The announcement stated that the increase in revenue was mainly due to higher sales of the FlashPressure caFFR pressure sensor. Additionally, the group's coronary cutting balloon, which was included in the centralized bulk purchase program, began to generate sales revenue of approximately 1.39 million yuan during the reporting period. With the ongoing promotion of centralized procurement policies and the gradual increase in the number of hospitals covered, the sales volume of this product is expected to steadily rise.